Translating N-Cadherin Targeted Therapy in Castrate Resistant Prostate Cancer

$256,992P50FY2013CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications, trials & patents

Paper 39669796 Paper 39589879 Paper 39503193 Paper 39484518 Paper 39426953 Paper 39402324 Paper 39294048 Paper 39228741 Paper 39155697 Paper 39096496 Paper 38867077 Paper 38746417 Paper 38585946 Paper 38580319 Paper 38536748 Paper 38494380 Paper 38270802 Paper 38244540 Paper 38177207 Paper 38026685 Paper 37973839 Paper 37963244 Paper 37775958 Paper 37548091 Paper 37399401 Paper 37192158 Paper 37179121 Paper 37084789 Paper 36905340 Paper 36759200 Paper 36608299 Paper 36028999 Paper 36007724 Paper 35971004 Paper 35869359 Paper 35694448 Paper 35534567 Paper 35075215 Paper 35040965 Paper 34774650 Paper 34675084 Paper 34671700 Paper 34378611 Paper 34170972 Paper 34052326 Paper 33962579 Paper 33908801 Paper 33762607 Paper 33711255 Paper 33602654 Paper 33537772 Paper 33441295 Paper 33427239 Paper 33402390 Paper 33392358 Paper 33386288 Paper 33277393 Paper 33199493 Paper 33197229 Paper 33037017 Paper 33035622 Paper 32694208 Paper 32690948 Paper 32647353 Paper 32562839 Paper 32544574 Paper 32505965 Paper 32380981 Paper 32311600 Paper 32194823 Paper 32086391 Paper 31932492 Paper 31871155 Paper 31825540 Paper 31718822 Paper 31439889 Paper 31390564 Trial NCT03596710 Trial NCT02830165 Trial NCT02176902 Trial NCT00798876 Patent 9987261 Patent 9896437 Patent 9527919 Patent 9388159 Patent 9126941 Patent 8940871 Patent 8940298 Patent 8802689 Patent 8703920 Patent 8680291 Patent 8648105 Patent 8445507 Patent 8183274 Patent 8110594 Patent 7943729 Patent 7803546 Patent 7709517 Patent 7420032 Patent 7384940

Abstract

Castration resistant metastatic disease is the major cause of morbidity and mortality in men with advanced prostate cancer. The molecular mechanisms underlying metastasis and castration resistance are both varied and only partially defined. Novel targets and therapies directed against these targets are urgently needed to combat advanced prostate cancer. Likewise, rational combination therapies directed against multiple critical targets are urgently needed. We have recently identified and

View original record on NIH RePORTER →